Head-to-Head

Briacell Therapeutics Corp. Common Shares vs. Eli Lilly & Co.

BCTX

Briacell Therapeutics Corp. Common Shares

$3.45 -1.43%

VS LLY

Eli Lilly & Co.

$1169.86 +4.86%

Eli Lilly & Co. (LLY) comes out ahead, leading on 4 of 6 compared factors.

Size & Scale

BCTXLLY
Market Cap $30.45 million $1.04 trillion
Revenue (TTM) — $65.18 billion
Net Income (TTM) $-30,976,383 $20.64 billion

LLY leads on 3 of 3 size & scale factors.

Valuation

BCTXLLY
P/E Ratio — 50.97
Price / Book 1.30 39.31
Price / Sales — 16.01

BCTX leads on 1 of 1 valuation factors.

Profitability

BCTXLLY
Net Margin — 31.67%
Return on Equity -132.33% 77.78%

LLY leads on 1 of 1 profitability factors.

Dividend

BCTXLLY
Dividend Yield — 0.59%
Payout Ratio — 30.15

BCTX and LLY split the dividend factors evenly.

Risk & Sentiment

BCTXLLY
Short Interest 0.29% 1.29%

BCTX leads on 1 of 1 risk & sentiment factors.

Dig deeper: BCTX overview, BCTX financials, LLY overview, LLY financials.

Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.